spacer
home > ict > winter 2019 > strategic success
PUBLICATIONS
International Clinical Trials

Strategic Success

ICT: With the addendum to the ICH E6 (R2) Guideline for Good Clinical Practice (GCP), the GCP has seen its first significant update in over 20 years. What is the new guideline and how does it impact clinical trial design?

Patrick Hughes: The ICH GCP Guidance Integrated Addendum provides a unified standard for the EU, Japan, the US, Canada, and Switzerland. The updated ICH E6 (R2) guidelines have been introduced to encourage the implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting, while continuing to ensure human subject protection and reliability of trial results. Far from being considered a hurdle to overcome, the ICH E6 (R2) should be a positive step forward and an exciting opportunity for more efficient clinical R&D, with significantly better outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Patrick Hughes is the Chief Commercial Officer at CluePoints. He holds a marketing degree from Newcastle University, UK, and a postgraduate marketing diploma in B2B marketing strategy from the Kellogg School of Management, US. Responsible for leading global sales, product, marketing, operational, and technical teams throughout his career, Patrick is a Senior Executive with over eighteen years of international commercial experience within life sciences, healthcare, and telecommunications.
spacer
Patrick Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement